content_top
34 companies, 1 interpreter! Insight, foresight
and recommendation
and recommendation
Histogenics Corporation (HSGX)
0.00
(0.00%)
content_middle
Histogenics Corporation (HSGX), a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace.
HSGX offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
HSGX has an exclusive channel collaboration agreement with Intrexon Corporation (XON) for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.
Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
Previous Close:
1.92
Open:
1.91
Bid:
1.75
Ask:
4.00
1yr Target Price:
6.00
Day's Range:
1.86 - 1.98
52wk Range:
0.08 - 3.05
Volume:
114011
Average Daily Volume:
60529
Market Capitalization:
29.33M
Trailing Annual Dividend Yield:
N/A
Shares Outstanding:
94.60M
content_right
- August 4, 2016 - 10:50pm | Earnings, Earnings Q2
- June 24, 2016 - 12:48pm | Research Notes
- March 7, 2016 - 9:39am | Henry'omics, Out and About
- February 3, 2016 - 9:07am | Research Notes
- December 21, 2015 - 10:08am | Research Notes
- November 16, 2015 - 10:34am | Earnings Q3
- July 30, 2015 - 9:22am | BOD & C-Suite Updates
- July 29, 2015 - 11:16am | Earnings Alert
- July 15, 2015 - 9:47am | BOD & C-Suite Updates
- June 22, 2015 - 9:59am | BOD & C-Suite Updates
- February 17, 2015 - 10:08am | Earnings Alert
- February 3, 2015 - 5:28am | BOD & C-Suite Updates
- February 2, 2015 - 4:14pm | BOD & C-Suite Updates
- December 18, 2014 - 9:34am | BOD & C-Suite Updates
- December 8, 2014 - 10:58am | Financings
- November 16, 2013 - 6:54pm | Research Notes